Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Idiopathic Parkinson Disease, Obesity
- Main trialPhase 2
- “This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-Baseline Period, a 28-day Open Label Treatment period (a participant receives active Dose A), and a 14-day Follow-Up Period.”In the company’s words, NCT06556173 on ClinicalTrials.gov
Other drugs for Idiopathic Parkinson Disease
- PembrolizumabMerck & Co. · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Intismeran autogeneMerck & Co. · Moderna · Phase 3
- LenvatinibMerck & Co. · Eisai · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- BHV-8000Biohaven · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 4 Apr 2025 | Phase 2a Study of VTX3232 in Parkinson's Disease | |
| Phase 2Completed | 10 Sep 2025 | Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026